Alnylam Pharma (ALNY) Posts Smaller-than-Expected Q1 Loss
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $247.51 -4.07%
Revenue Growth %: +15.3%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.3%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.22), $0.25 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $30.15 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- RH shares jump after second quarter beat
- Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
